Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
$4.19-0.36%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-47.0%
The outlook
Capricor Therapeutics, Inc. currently reads as neutral based on buy — 2.1 avg of 7 analysts, below its 50- & 200-day averages, 3% of the way from its 52-week low to high, avg target +858% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusBuy — 2.1 avg of 7 analysts
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +858% vs current price
Analyst price target
~12-month · 7 analysts$40.14average target+858.1% vs now
Now $4.19
Low $7.00High $60.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$242.7M
52-wk high
$40.37
52-wk low
$2.96
50-day avg
$24.08
200-day avg
$23.31
Trailing P/E
—